Intervention

Perjeta

ClinicalTrials.gov intervention label

Clinical trials5

Recruiting0

Common conditions4

Lead sponsors shown4

Clinical trials

5 shown

Efficacy and Safety Study of EG1206A (EirGenix' Pertuzumab) Compared With EU-sourced Perjeta® (Pertuzumab) in Patients With HER2-positive Hormone Receptor Negative Early Breast Cancer.NCT06884254 · 2025-05-01

Clinical Study of the Efficacy and Safety of BCD-178 and Perjeta® as Neoadjuvant Therapy of HER2-Positive Breast CancerNCT05802225 · 2023-01-30

ACTIVE_NOT_RECRUITING

A Double-Blind, Comparative, Randomized Clinical Study of the Pharmacokinetics, Safety, and Immunogenicity of a Single Intravenous Infusion of BCD-178 or Perjeta® in Healthy VolunteersNCT05738993 · 2022-08-08

Assessing the Response Rate of Neo-adjuvant Paclitaxel (Taxol) in Nigerian Women With Breast CancerNCT03058939 · 2018-11-01

Chemotherapy-free Trastuzumab and Pertuzumab in HER2-positive Breast Cancer: FDG-PET Response-adapted Strategy.NCT03161353 · 2017-06-26

ACTIVE_NOT_RECRUITING

Common conditions

Breast Cancer4 Breast Cancer Stage II1 Breast Cancer Stage III1 Early Breast Cancer1

Leading sponsors

Biocad2 EirGenix, Inc.1 MedSIR1 University of Chicago1

Trial status mix

ACTIVE_NOT_RECRUITING2

WITHDRAWN2

UNKNOWN1

Phase mix

PHASE22

PHASE32

PHASE11

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.